Special Issue

Interferon Responses after Vaccine Administration

Message from the Guest Editors

Interferons (IFNs) are a family of proteins that cells exhibiting productive effects in response to infection or other stressors. They play a critical role in immune responses by activating antiviral defenses, stimulating the production of antibodies, and recruiting immune cells to the site of infection. The role of IFNs in the immune response to vaccines is becoming increasingly recognized. IFNs can enhance the production of antibodies and other immune responses to vaccines, and they can also help to protect against vaccine-preventable diseases. The articles in this Special Issue will explore the latest research on the role of IFNs in the immune response to vaccines. They will discuss how IFNs interact with other components of the immune system, how IFNs can be used to improve the efficacy of vaccines, and the safety and efficacy of IFNs in vaccine development. This special issue will be of interest to researchers and clinicians working in the fields of immunology, vaccinology, and infectious diseases.

Guest Editors

Dr. Luis Ignacio González-Granado
University Hospital 12 Octubre, Complutense University of Madrid, Madrid, Spain
Dr. Hugh Thomson Reyburn
CSIC-Centro Nacional de Biotecnologia (CNB), Madrid, Spain

Deadline for manuscript submissions

closed (31 July 2024)

Vaccines

an Open Access Journal by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed

mdpi.com/si/185591

Vaccines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
vaccines@mdpi.com

mdpi.com/journal/vaccines

Vaccines

an Open Access Journal by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed

mdpi.com/journal/vaccines

About the Journal

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X), founded in 2013, now has a firm history of publishing peer-reviewed, state-of-the-art research papers on vaccines and vaccination in the broadest sense. Areas covered include, but are not limited to, novel and emerging vaccine technologies, building on in-depth knowledge of what constitutes a protective immune response. These can be new vaccines for old diseases, or old vaccines for new diseases. Vaccines against cancer and autoimmune diseases explicitly are also within the scope of the journal. Because public opinion and even government policies towards vaccines and vaccination have changed, vaccine policy and public health issues are major concerns. Climate change will also have an impact on the spread of infectious diseases, and thus also on vaccine and vaccination policies worldwide.

Editor-in-Chief

Prof. Dr. Ger Rijkers
Department of Health, Cognition and Behavior, University College Roosevelt, 4331 CB Middelburg, The Netherlands

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) / CiteScore - Q1 (Pharmacology (medical))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 18.1 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the second half of 2025).

MDPI